Micvotabart pelidotin
Antibody–drug conjugate
Also known as PYX-201
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
Company guidance: data expected December 2026 (Pyxis Oncology, 5 Nov 2026). “We plan to provide a corporate update in December 2026 that we expect will outline a comprehensive development strategy for MICVO in R/M HNSCC, including how emerging combination data inform potential opportunities across treatment settings, and will include updated efficacy and safety data from the ongoing PYX-201-102 Phase 1/2 dose escalation study evaluating MICVO in combination with KEYTRUDA ® (pembrolizumab) across multiple doses in 1L R/M HNSCC.” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT06795412 NCT06795412 · Solid Tumors Registry: NCT06795412 | 1/2 | Number of Participants who Experience a Dose-Limiting Toxicity (DLT) (Day 1 to Day 21); Number of Participants who Experience an Adverse Event (AE) (Up to approximately 2 years); Number of Participants who Experience Clinically Significant Changes in Clinical Laboratory Parameters (Up to approximately 2 years); Number of Participants who Experience Clinically Significant Changes in Vital Signs (Up to approximately 2 years); Number of Participants who Experience Clinically Significant Changes in electrocardiogram (ECG) Parameters (Up to approximately 2 years) 2027-12-06 | In progress: results expected 6 Dec 2027 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1/2 (1)
What this study did
Phase 1 (1)
What this study did
Competitive landscape
This drug's own stage for Solid Tumors: Phase 1/2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Micvotabart Pelidotin: this drug | Phase 1/2 | Antibody–drug conjugate | ED-B domain of fibronectin | not yet graded | No reviewed efficacy summary in this indication | |
| Larotrectinib | Approved | Small molecule | TRK (TRKA/TRKB/TRKC, encoded by NTRK1/NTRK2/NTRK3 gene fusions) | Weak signal | No reviewed efficacy summary in this indication | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex) | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Repotrectinib | Approved | Small molecule | ROS1/NTRK | not yet graded | No reviewed efficacy summary in this indication | |
| Selpercatinib (Retevmo) | Approved | Small molecule | RET | not yet graded | No reviewed efficacy summary in this indication | |
| ALG.APV-527 | Phase 1/2 | Multispecific antibody | 4-1BB (CD137) x 5T4 | not yet graded | No reviewed efficacy summary in this indication | |
| CR-001 | Phase 1/2(overall) | Multispecific antibody | PD-1 + VEGF | not yet graded | No reviewed efficacy summary in this indication | |
| EB-SELECT Dual-Target CAR-NK Cells | Phase 1/2 | Cell therapy | Tumor antigen menu (TROP2, MSLN, B7-H3, HER2) | not yet graded | No reviewed efficacy summary in this indication | |
| EB-SELECT Single-Target CAR-NK Cells | Phase 1/2 | Cell therapy | Personalized, biomarker-guided allogeneic chimeric antigen receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Linebacker | —(overall) | Small molecule | PIM kinases (PIM1/2/3) | not yet graded | No reviewed efficacy summary in this indication | |
| RP3 | Discontinued | Oncolytic virus | Tumor cells (oncolytic replication) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Micvotabart pelidotin to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent